van Dinther Dieke, Stolk Dorian A, van de Ven Rieneke, van Kooyk Yvette, de Gruijl Tanja D, den Haan Joke M M
Department of Molecular Cell Biology and Immunology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands; and.
Department of Medical Oncology, Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands.
J Leukoc Biol. 2017 Oct;102(4):1017-1034. doi: 10.1189/jlb.5MR0217-059RR. Epub 2017 Jul 20.
There is a growing understanding of why certain patients do or do not respond to checkpoint inhibition therapy. This opens new opportunities to reconsider and redevelop vaccine strategies to prime an anticancer immune response. Combination of such vaccines with checkpoint inhibitors will both provide the fuel and release the brake for an efficient anticancer response. Here, we discuss vaccine strategies that use C-type lectin receptor (CLR) targeting of APCs, such as dendritic cells and macrophages. APCs are a necessity for the priming of antigen-specific cytotoxic and helper T cells. Because CLRs are natural carbohydrate-recognition receptors highly expressed by multiple subsets of APCs and involved in uptake and processing of Ags for presentation, these receptors seem particularly interesting for targeting purposes.
人们对于某些患者为何对检查点抑制疗法有反应或无反应的理解日益加深。这为重新考虑和重新开发疫苗策略以启动抗癌免疫反应带来了新机遇。此类疫苗与检查点抑制剂联合使用，将既提供动力又解除刹车，以实现高效的抗癌反应。在此，我们讨论利用C型凝集素受体（CLR）靶向抗原呈递细胞（APC）（如树突状细胞和巨噬细胞）的疫苗策略。APC是启动抗原特异性细胞毒性T细胞和辅助性T细胞的必要条件。由于CLR是由多个APC亚群高度表达的天然碳水化合物识别受体，且参与抗原的摄取和加工以进行呈递，因此这些受体似乎特别适合用于靶向目的。
